| Literature DB >> 31091466 |
Ivana Kurelac1, Nikkitha Umesh Ganesh2, Maria Iorio3, Anna Maria Porcelli4, Giuseppe Gasparre5.
Abstract
The efficacy of metformin in treating cancer has been extensively investigated since epidemiologic studies associated this anti-diabetic drug with a lower risk of cancer incidence. Since tumors are complex systems, in which cancer cells coexist and interact with several different types of non-malignant cells, it is not surprising that anti-cancer drugs affect not only cancer cells, but also the abundance and functions of cells of the tumor microenvironment. Recent years have seen a wide collection of reports showing how metformin, as well as other complex I inhibitors, may influence cancer progression by modulating the phenotype of non-transformed cells in a tumor. In this review, we particularly focus on the effect of metformin on angiogenesis, cancer-associated fibroblasts, tumor-associated macrophages and cancer immunosuppression.Entities:
Keywords: Angiogenesis; Cancer immunosuppression; Cancer metabolism; Cancer-associated fibroblasts; Metformin; Respiratory complex I; Tumor microenvironment; Tumor-associated macrophages
Mesh：
Substances：
Year: 2019 PMID： 31091466 DOI： 10.1016/j.semcdb.2019.05.010
Source DB: PubMed Journal: Semin Cell Dev Biol ISSN： 1084-9521 Impact factor: 7.727